Last updated: February 28, 2026
What is LORABID?
LORABID is a generic version of Lorazepam, marketed under the brand name LORABID. Lorazepam is a benzodiazepine used primarily for anxiety, insomnia, and seizure disorders. It has a well-established safety and efficacy profile, with its patent expiring in the early 2010s, leading to increased generic competition.
Market Overview
LORABID competes within the global anxiolytics market, estimated at approximately USD 9.2 billion in 2022. The market is characterized by high demand for benzodiazepines, driven by the prevalence of anxiety and sleep disorders.
Generic availability has capped the pricing of Lorazepam, leading to a commoditized market. The U.S. accounts for roughly 55% of global sales, with Europe and other markets representing the remainder.
Patent and Regulatory Status
Lorazepam patents expired in the U.S. in 2014, opening the market to generics. Regulatory pathways for approval include:
- Abbreviated New Drug Application (ANDA) in the U.S.
- Marketing Authorization Application (MAA) in Europe.
Generic LORABID manufacturers must demonstrate bioequivalence to the brand-name drug, with approval times typically 12-24 months post-application.
Competitive Landscape
Major competitors include:
- Teva Pharmaceuticals
- Mylan (now part of Viatris)
- Sun Pharmaceutical
- Sandoz (Novartis)
Market share is fragmented; however, existing giants hold significant scale advantages.
Investment Fundamentals
Revenue Potential
- Source: ~USD 7 billion global lorazepam sales annually (pre-generic saturation).
- Pricing: Average wholesale price (AWP) for generics in the U.S. averages USD 0.10 per tablet.
- Market share: A new entrant can target 10-15% of U.S. market within 2-3 years with aggressive distribution.
Cost Structure
- Bioequivalence testing costs: approximately USD 2-3 million.
- Manufacturing setup: USD 3-5 million for equipment and validation.
- Regulatory filing fees: USD 1 million+.
- Ongoing marketing and distribution costs: variable but minimal for generics.
Timing
- Approval pathway: 12-24 months from filing.
- Entry timeline: potential launch within 18-30 months post-approval.
- Market penetration: achievable with targeted sales efforts within 2-3 years.
Risks
- Regulatory delays can extend time to market.
- Price erosion due to generic competition.
- Supply chain disruptions affecting manufacturing.
- Intellectual property risk if patent disputes arise in specific jurisdictions.
Financial Modeling Assumptions
| Metric |
Assumption |
| Market share within 3 years |
10-15% US market |
| Average price per tablet |
USD 0.10 |
| Annual sales volume (US) |
200 million tablets (initial estimate) |
| Gross margin |
70-80% based on generic pricing and manufacturing costs |
| R&D and regulatory costs |
USD 4 million upfront, USD 0.5 million annually |
Investment Outlook
LORABID offers a low-cost, high-margin opportunity with predictable revenue streams once regulatory approval is obtained. The main value drivers are speed to market, regulatory navigation, and efficient scale-up.
The key challenge involves timing and competitive pricing pressures. The rapidly saturating generics market limits long-term price growth but maintains stable cash flow.
Key Risks and Mitigation Strategies
- Regulatory delays: Engage with regulators early, ensure compliance.
- Price erosion: Differentiate through supply reliability, minor formulation improvements.
- Market entry timing: Accelerate approval process through strategic partnerships.
Key Takeaways
- LORABID is a generic Lorazepam targeting an established, high-volume market.
- The main investment hurdle is obtaining regulatory approval efficiently.
- Revenue potential hinges on capturing a minority share within a saturated market.
- Cost structure is predictable; initial R&D and regulatory costs are capped.
- Market risks include pricing pressure and supply chain disruptions.
FAQs
1. What are the main regulatory pathways for LORABID approval?
Generic Lorazepam approvals are primarily through ANDA in the U.S. and MAA in Europe, requiring demonstration of bioequivalence.
2. How long does it take to bring LORABID to market?
Approval can take 12-24 months post-application. Manufacturing and distribution setup can add another 6-12 months.
3. What is the competitive advantage of a new generic Lorazepam product?
Speed to market, reliable supply chain, and pricing strategies can enable capturing a meaningful share in a saturated market.
4. What are the primary licensing and patent considerations?
Patent expiry in major markets occurred around 2014, but patent disputes and market exclusivity opportunities can still pose barriers in select jurisdictions.
5. How does market saturation affect profitability?
High competition pressures reduce margins but ensure stable demand, especially for established drugs like Lorazepam, which have predictable prescribing patterns.
References
[1] IQVIA. (2022). Global Pharmaceuticals Market Report.
[2] FDA. (2014). Approved Drug Products: Lorazepam.
[3] Statista. (2022). Global anxiolytics market size.
[4] EvaluatePharma. (2022). Generic drug market outlook.
[5] European Medicines Agency. (2022). Marketing authorization procedures.
